0001209191-23-014908.txt : 20230302 0001209191-23-014908.hdr.sgml : 20230302 20230302182825 ACCESSION NUMBER: 0001209191-23-014908 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230301 FILED AS OF DATE: 20230302 DATE AS OF CHANGE: 20230302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mylet Johanna CENTRAL INDEX KEY: 0001765988 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39376 FILM NUMBER: 23700844 MAIL ADDRESS: STREET 1: C/O POSEIDA THERAPEUTICS, INC. STREET 2: 4242 CAMPUS POINT COURT, SUITE 700 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Poseida Therapeutics, Inc. CENTRAL INDEX KEY: 0001661460 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472846548 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-779-3100 MAIL ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-01 0 0001661460 Poseida Therapeutics, Inc. PSTX 0001765988 Mylet Johanna C/O POSEIDA THERAPEUTICS, INC. 9390 TOWNE CENTRE DRIVE, STE 200 SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer Common Stock 2023-03-01 4 A 0 92772 0.00 A 181954 D Common Stock 2023-03-01 4 F 0 4323 5.35 D 177631 D Employee Stock Option (Right to Buy) 5.35 2023-03-01 4 A 0 125283 0.00 A 2033-02-28 Common Stock 125283 125283 D Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments. Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on March 18, 2022, and 1,951 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on September 20, 2022. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on March 1, 2022. 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter. /s/ Harry J. Leonhardt, Attorney-in-Fact 2023-03-02